Adjuvant chemoradiotherapy plus pembrolizumab for locally advanced esophageal squamous cell carcinoma with high risk of recurrence following neoadjuvant chemoradiotherapy: a single-arm phase II study
Adjuvant chemoradiotherapy followed by pembrolizumab is feasible and may be associated with improved 1-year RFS rate in patients at high risk of recurrence after trimodality therapy for locally advanced ESCC. Trial registration number ClinicalTrials.gov (No. NCT03322267).
Authors
- Jason Chia‐Hsien Cheng (ORCID: https://orcid.org/0000-0002-2007-0220)
- Jhe‐Cyuan Guo (ORCID: https://orcid.org/0000-0002-6689-9640)
- Jang‐Ming Lee (ORCID: https://orcid.org/0000-0001-9727-227X)
- Pei‐Ming Huang (ORCID: https://orcid.org/0000-0001-5493-7673)
- Min-Shu Hsieh
- Hung‐Yang Kuo (ORCID: https://orcid.org/0000-0002-0573-2636)
- Chih‐Hung Hsu (ORCID: https://orcid.org/0000-0003-0495-973X)
- Shuling Wu
- Chia-Chi Lin
- Ta-Chen Huang (ORCID: https://orcid.org/0000-0001-8065-2057)
- Yen-Lin Huang
- Feng-Ming Hsu
Institutions
- National Taiwan University (TW)
- National Taiwan University Hospital (TW)
- Taipei Medical University (TW)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1007/s00262-024-03826-y
- Citations
- 3
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.72
Funders
- Merck Sharp and Dohme